ESTRO 2024 - Abstract Book

S2001

Clinical - Mixed sites, palliation

ESTRO 2024

Keywords: SABR, SBRT, liver metastases

References:

1. McDermott R, Dunne E, Zhao Y, Bergman A, Liu M, Schellenberg D, Ma R. Stereotactic ablative radiotherapy for colorectal liver metastases. Clinical colorectal cancer. 2022 Nov 10; 22(1):120-128. https://doi.org/10.1016/j.clcc.2022.10.006

2987

Digital Poster

Treatment outcomes of SABR on oligometastases from rare primary cancers

Rupinder Talwar, Julie Duong, Prasana Nariyangadu, Karen Venables, Peter Hoskin, Mark Harrison, Robert Hughes, Roberto Alonzi, Romaana Mir, Nicola Anyamene, Anup Vinayan, Peter Ostler, Nihal Shah, Suraiya Dubash, Yat Tsang

Mount Vernon Cancer Centre, Oncology, London, United Kingdom

Purpose/Objective:

There is limited literature on clinical outcomes of stereotactic ablative body radiotherapy (SABR) to oligometastases from head and neck cancer, upper GI, renal, urinary (bladder, urethra, ureter), gynaecological, sarcoma and skin cancers. These are often termed as rare primary cancers (RPC). This study investigates what factors influence SABR clinical outcomes in patients with oligometastases from RPC.

Material/Methods:

Treatment records of patients with oligometastases from RPC were retrospectively reviewed from a single institution’s database. All patients were treated with a dedicated robotic stereotactic radiotherapy (RT) machine under free breathing with real time motion tracking image guided RT. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier methods and post RT toxicities were scored following the CTCAE v4.0. Log-rank tests were used for the analysis of prognostic factors on OS and PFS as listed in Table 1.

Table 1